In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

We read with interest the article by She et al. [ [1] She L. Hu H. Liao M. et al. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer. 2019; 138: 88-94 Abstract Full Text Full Text PDF PubMed Scopus (31) Google Scholar ] “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) 1% or greater,” which was published in Lung Cancer (2019, volume 138). We compared this study with our previously published cost-effectiveness analysis in the same population and would like to point out the differences in methodologies and results and discuss the reasons for the different conclusions. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greaterLung CancerVol. 138PreviewLung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide, with 2.1 million new lung cancer cases and 1.8 million deaths per year [1–4]. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Up to 61% of patients have advanced disease at the time of diagnosis, with a 5-year survival rate of 18% [5,6]. Full-Text PDF